Eisai Expands Lecanemab Access with At-Home Autoinjector for Early Alzheimer's — Eisai Inc.

Event summary

Eisai's LEQEMBI IQLIK autoinjector for lecanemab-irmb is now available in the U.S. for early Alzheimer's disease initiation therapy.
The subcutaneous injection offers a convenient alternative to IV dosing, with a 500 mg weekly regimen delivered in ~15 seconds.
Eisai and Biogen provide support resources including a companion app, welcome kits, and financial assistance programs.
LEQEMBI has been approved in 53 countries and is under regulatory review in 6 additional countries.
The treatment showed a 27% slowing of disease progression in the Clarity AD clinical trial.

The big picture

The launch of LEQEMBI IQLIK represents a significant step in making Alzheimer's treatment more accessible and convenient. This shift to at-home administration could lower barriers to treatment initiation and maintenance, potentially expanding the patient population that can benefit from anti-amyloid therapy. The strategic partnership between Eisai and Biogen continues to drive innovation in neurological disease treatment, with lecanemab now approved in multiple major markets.

What we're watching

Market Adoption: How quickly physicians and patients will transition from IV to at-home subcutaneous administration.
Regulatory Expansion: Whether approvals in additional countries will accelerate, particularly in major markets like Japan and China.
Competitive Dynamics: How Eisai and Biogen will position LEQEMBI against emerging Alzheimer's treatments in development.